Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-I: Introduction01:29

Asthma-I: Introduction

3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same author

Mucus Plug Formation is Associated with Eosinophilic Activation in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2026
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Reply to Zhao et al.: Clarifying Structural - Functional Coupling by FeNO Status in VESTIGE.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Jan 10, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K

Targeted Treatment in Asthma-Opportunities and Challenges.

Ioana Agache1, Magdalena Zemelka-Wiacek2, Radosław Gawlik3

  • 1Faculty of Medicine, Transylvania University, Brasov, Romania.

The Journal of Allergy and Clinical Immunology. in Practice
|November 28, 2025
PubMed
Summary
This summary is machine-generated.

Targeted asthma treatment is advancing for specific patients, focusing on defining remission, stratifying mild asthma, and discovering biomarkers. Implementation requires addressing resource barriers for better patient outcomes.

Keywords:
AsthmaBiologicsBiomarkerEndotypeMild asthmaPersonalized medicineRemissionTargeted treatment

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

885

Related Experiment Videos

Last Updated: Jan 10, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.4K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.4K
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
04:04

Asthma Detection Research Based on Voice Signal Processing and Machine Learning

Published on: July 22, 2025

885

Area of Science:

  • Allergy and Immunology
  • Respiratory Medicine
  • Precision Medicine

Background:

  • Targeted asthma treatment is an emerging goal but not yet standard care.
  • Expert insights from the Central and Southern European Allergy and Asthma Alliance (CSEA3) 2025 meeting inform future directions.
  • Current asthma management pathways need refinement for personalized approaches.

Purpose of the Study:

  • To outline key priorities for advancing targeted asthma management.
  • To identify strategies for implementing stratified care in asthma.
  • To address challenges in personalized asthma treatment adoption.

Main Methods:

  • Review of expert discussions and insights from the 2025 CSEA3 meeting.
  • Identification and synthesis of key priorities for targeted asthma therapy.
  • Analysis of barriers and facilitators for stratified asthma care implementation.

Main Results:

  • Four key priorities identified: defining remission, managing mild asthma via stratification, biomarker discovery, and optimizing implementation.
  • Patient stratification by endotype and risk profile may improve mild asthma management.
  • Need for predictive, point-of-care biomarkers and validation of digital tools for implementation.

Conclusions:

  • Advancing targeted asthma treatment requires a universally accepted definition of remission.
  • Stratified care, biomarker discovery, and addressing implementation barriers are crucial for personalized asthma management.
  • Coordinated efforts are essential to translate personalized treatment advances into sustainable, improved patient outcomes, especially in resource-limited settings.